Symbols / VYNE $0.60 +0.45% VYNE Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
VYNE Chart
About

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 20.12M
Enterprise Value -8.98M Income -26.74M Sales 570.00K
Book/sh 0.83 Cash/sh 0.87 Dividend Yield —
Payout 0.00% Employees 10 IPO —
P/E — Forward P/E -0.37 PEG —
P/S 35.29 P/B 0.72 P/C —
EV/EBITDA 0.30 EV/Sales -15.76 Quick Ratio 12.11
Current Ratio 12.53 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.63 EPS next Y -1.65 EPS Growth —
Revenue Growth 54.80% Earnings 2026-02-27 08:00 ROA -38.31%
ROE -66.96% ROIC — Gross Margin 100.00%
Oper. Margin -40.15% Profit Margin 0.00% Shs Outstand 33.32M
Shs Float 32.50M Short Float 0.57% Short Ratio 0.60
Short Interest — 52W High 1.99 52W Low 0.28
Beta 1.95 Avg Volume 332.09K Volume 170.66K
Target Price $2.00 Recom None Prev Close $0.60
Price $0.60 Change 0.45%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.00
Mean price target
2. Current target
$0.60
Latest analyst target
3. DCF / Fair value
$-14.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.60
Low
$2.00
High
$2.00
Mean
$2.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-07-30 down HC Wainwright & Co. Buy → Neutral —
2025-04-25 main HC Wainwright & Co. Buy → Buy $5
2025-03-06 reit HC Wainwright & Co. Buy → Buy $6
2025-02-19 reit HC Wainwright & Co. Buy → Buy $6
2025-01-14 reit HC Wainwright & Co. Buy → Buy $6
2025-01-06 reit HC Wainwright & Co. Buy → Buy $6
2024-12-23 reit HC Wainwright & Co. Buy → Buy $6
2024-11-18 init BTIG — → Buy $8
2024-11-08 reit HC Wainwright & Co. Buy → Buy $6
2024-09-12 reit HC Wainwright & Co. Buy → Buy $6
2024-08-15 reit HC Wainwright & Co. Buy → Buy $6
2024-06-14 reit HC Wainwright & Co. Buy → Buy $6
2024-06-05 reit HC Wainwright & Co. Buy → Buy $6
2024-05-09 reit HC Wainwright & Co. Buy → Buy $6
2024-05-06 reit HC Wainwright & Co. Buy → Buy $6
2024-02-29 reit HC Wainwright & Co. Buy → Buy $6
2023-10-30 main HC Wainwright & Co. Buy → Buy $6
2023-08-14 reit HC Wainwright & Co. Buy → Buy $28
2023-05-12 main Cantor Fitzgerald — → Overweight $9
2023-05-12 reit HC Wainwright & Co. Buy → Buy $28
News
RSS: Latest VYNE news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-06-02 HARSCH MUTYA FONTE General Counsel — 1,145 $0.81 $927
2025-06-02 DOMZALSKI DAVID T Chief Executive Officer — 8,681 $0.81 $7,032
2025-01-15 LEPORE PATRICK G Director — 15,000 $2.92 $43,800
2024-11-29 DOMZALSKI DAVID T Chief Executive Officer — 3,901 $2.96 $11,547
2024-05-31 DOMZALSKI DAVID T Chief Executive Officer — 4,429 $2.16 $9,562
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.57
+13.77%
0.50
+18.16%
0.42
-11.11%
0.48
Operating Revenue
0.57
+13.77%
0.50
+18.16%
0.42
-11.11%
0.48
Cost Of Revenue
—
—
—
—
Reconciled Cost Of Revenue
—
—
—
—
Gross Profit
—
—
—
—
Operating Expense
30.32
-31.31%
44.14
+48.70%
29.68
-14.64%
34.77
Research And Development
19.24
-37.84%
30.95
+89.77%
16.31
-11.30%
18.39
Selling General And Administration
11.08
-15.99%
13.19
-1.37%
13.38
-18.38%
16.39
General And Administrative Expense
11.08
-15.99%
13.19
-1.37%
13.38
-18.38%
16.39
Other Gand A
11.08
-15.99%
13.19
-1.37%
13.38
-18.38%
16.39
Total Expenses
30.32
-31.31%
44.14
+48.70%
29.68
-14.64%
34.77
Operating Income
-29.75
+31.83%
-43.64
-49.15%
-29.26
+14.69%
-34.30
Total Operating Income As Reported
-29.75
+31.83%
-43.64
-49.15%
-29.26
+14.69%
-34.30
EBITDA
-29.73
+31.87%
-43.63
-49.13%
-29.26
+14.51%
-34.22
Normalized EBITDA
-29.73
+31.87%
-43.63
-49.13%
-29.26
+14.51%
-34.22
Reconciled Depreciation
0.02
+475.00%
0.00
0.00
-100.00%
0.07
EBIT
-29.75
+31.83%
-43.64
-49.15%
-29.26
+14.69%
-34.30
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Special Income Charges
—
—
—
—
Impairment Of Capital Assets
—
—
—
—
Net Income
-26.48
+33.52%
-39.83
-40.00%
-28.45
-22.59%
-23.21
Pretax Income
-26.73
+32.84%
-39.80
-42.81%
-27.87
+17.86%
-33.93
Net Non Operating Interest Income Expense
—
—
—
0.00
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
—
—
—
0.00
Interest Expense
—
—
—
0.00
Other Income Expense
3.02
-21.31%
3.83
+176.62%
1.39
+281.82%
0.36
Other Non Operating Income Expenses
3.02
-21.31%
3.83
+176.62%
1.39
+281.82%
0.36
Tax Provision
0.00
+0.00%
0.00
0.00
-100.00%
0.01
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.48
+33.52%
-39.83
-40.00%
-28.45
-22.59%
-23.21
Net Income From Continuing Operation Net Minority Interest
-26.74
+32.84%
-39.81
-42.82%
-27.87
+17.89%
-33.95
Net Income From Continuing And Discontinued Operation
-26.48
+33.52%
-39.83
-40.00%
-28.45
-22.59%
-23.21
Net Income Continuous Operations
-26.74
+32.84%
-39.81
-42.82%
-27.87
+17.89%
-33.95
Net Income Discontinuous Operations
0.25
+1037.04%
-0.03
+95.34%
-0.58
-105.40%
10.73
Normalized Income
-26.74
+32.84%
-39.81
-42.82%
-27.87
+17.89%
-33.95
Net Income Common Stockholders
-26.48
+33.52%
-39.83
-40.00%
-28.45
-22.59%
-23.21
Diluted EPS
—
-0.93
+66.55%
-2.78
+61.81%
-7.28
Basic EPS
—
-0.93
+66.55%
-2.78
+61.81%
-7.28
Basic Average Shares
—
42.59
+314.57%
10.27
+222.44%
3.19
Diluted Average Shares
—
42.59
+314.57%
10.27
+222.44%
3.19
Diluted NI Availto Com Stockholders
-26.48
+33.52%
-39.83
-40.00%
-28.45
-22.59%
-23.21
Line Item Trend 2023-12-31
Total Assets
97.69
Current Assets
95.96
Cash Cash Equivalents And Short Term Investments
93.25
Cash And Cash Equivalents
30.62
Other Short Term Investments
62.63
Receivables
0.00
Accounts Receivable
—
Inventory
—
Raw Materials
—
Work In Process
—
Finished Goods
—
Prepaid Assets
—
Restricted Cash
0.05
Assets Held For Sale Current
—
Other Current Assets
2.66
Total Non Current Assets
1.72
Net PPE
0.21
Gross PPE
0.21
Accumulated Depreciation
—
Properties
0.00
Buildings And Improvements
0.21
Machinery Furniture Equipment
—
Other Properties
—
Leases
—
Non Current Prepaid Assets
—
Other Non Current Assets
1.51
Total Liabilities Net Minority Interest
8.95
Current Liabilities
7.54
Payables And Accrued Expenses
3.53
Payables
1.66
Accounts Payable
1.66
Current Accrued Expenses
1.87
Pensionand Other Post Retirement Benefit Plans Current
1.65
Current Debt And Capital Lease Obligation
0.12
Current Capital Lease Obligation
0.12
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
1.41
Long Term Debt And Capital Lease Obligation
0.10
Long Term Capital Lease Obligation
0.10
Other Non Current Liabilities
1.31
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
88.73
Common Stock Equity
88.73
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
14.10
Ordinary Shares Number
14.10
Treasury Shares Number
0.00
Additional Paid In Capital
780.04
Retained Earnings
-691.34
Gains Losses Not Affecting Retained Earnings
0.03
Other Equity Adjustments
0.03
Total Equity Gross Minority Interest
88.73
Total Capitalization
88.73
Working Capital
88.42
Invested Capital
88.73
Total Debt
0.21
Capital Lease Obligations
0.21
Net Tangible Assets
88.73
Tangible Book Value
88.73
Current Provisions
2.25
Duefrom Related Parties Current
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-33.12
+2.50%
-33.97
-34.06%
-25.34
+13.22%
-29.20
Cash Flow From Continuing Operating Activities
-33.12
+2.50%
-33.97
-34.06%
-25.34
+13.22%
-29.20
Net Income From Continuing Operations
-26.48
+33.52%
-39.83
-40.00%
-28.45
-22.59%
-23.21
Depreciation Amortization Depletion
0.02
+475.00%
0.00
0.00
-100.00%
0.07
Depreciation
0.02
+475.00%
0.00
0.00
-100.00%
0.07
Depreciation And Amortization
0.02
+475.00%
0.00
0.00
-100.00%
0.07
Other Non Cash Items
—
—
—
—
Stock Based Compensation
2.31
-30.12%
3.30
-0.06%
3.31
-23.09%
4.30
Asset Impairment Charge
—
—
—
—
Operating Gains Losses
—
—
—
-12.64
Unrealized Gain Loss On Investment Securities
0.00
+100.00%
-0.00
-200.00%
0.00
0.00
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.28
Change In Working Capital
-8.19
-263.91%
5.00
+8231.67%
0.06
-97.36%
2.28
Change In Receivables
4.21
+568.74%
-0.90
-321.98%
0.41
-96.39%
11.21
Changes In Account Receivables
4.21
+568.74%
-0.90
-321.98%
0.41
-96.39%
11.21
Change In Inventory
—
—
0.00
-100.00%
0.10
Change In Payables And Accrued Expense
-12.31
-304.74%
6.01
+1175.49%
-0.56
+93.56%
-8.68
Change In Payable
-12.31
-304.74%
6.01
+1175.49%
-0.56
+93.56%
-8.68
Change In Account Payable
-12.31
-304.74%
6.01
+1175.49%
-0.56
+93.56%
-8.68
Change In Other Current Assets
—
—
—
0.00
Change In Other Current Liabilities
-0.10
+13.16%
-0.11
-153.27%
0.21
+161.32%
-0.35
Investing Cash Flow
37.37
+59.93%
23.36
+140.74%
-57.35
-466.08%
15.67
Cash Flow From Continuing Investing Activities
37.37
+59.93%
23.36
+140.74%
-57.35
-466.08%
15.67
Net PPE Purchase And Sale
0.00
+100.00%
-0.12
0.00
—
Purchase Of PPE
0.00
+100.00%
-0.12
0.00
—
Capital Expenditure
—
-0.12
—
—
Net Investment Purchase And Sale
37.37
+59.13%
23.48
+137.66%
-62.35
0.00
Purchase Of Investment
-30.93
+48.89%
-60.52
+2.94%
-62.35
0.00
Sale Of Investment
68.30
-18.69%
84.00
0.00
0.00
Net Business Purchase And Sale
—
0.00
-100.00%
5.00
-68.09%
15.67
Gain Loss On Sale Of Business
—
—
0.00
+100.00%
-12.92
Financing Cash Flow
-0.14
-1.42%
-0.14
-100.17%
82.39
+4884.51%
1.65
Cash Flow From Continuing Financing Activities
-0.14
-1.42%
-0.14
-100.17%
82.39
+4884.51%
1.65
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
—
0.00
-100.00%
82.82
+5534.08%
1.47
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.36
—
Proceeds From Stock Option Exercised
-0.14
-1.42%
-0.14
-110.45%
-0.07
-139.29%
-0.03
Net Other Financing Charges
—
—
—
—
Changes In Cash
4.10
+138.16%
-10.75
-3470.76%
-0.30
+97.47%
-11.88
Effect Of Exchange Rate Changes
—
—
—
—
Beginning Cash Position
19.93
-35.04%
30.67
-0.97%
30.98
-27.72%
42.85
End Cash Position
24.03
+20.58%
19.93
-35.04%
30.67
-0.97%
30.98
Free Cash Flow
-33.12
+2.83%
-34.09
-34.52%
-25.34
+13.22%
-29.20
Interest Paid Supplemental Data
—
—
—
0.00
Amortization Of Securities
-0.78
+68.15%
-2.44
-858.04%
-0.26
0.00
Common Stock Issuance
—
0.00
-100.00%
82.82
+5534.08%
1.47
Issuance Of Capital Stock
—
0.00
-100.00%
82.82
+4826.89%
1.68
Net Preferred Stock Issuance
—
0.00
+100.00%
-0.36
-270.62%
0.21
Preferred Stock Issuance
—
—
—
0.21
Preferred Stock Payments
—
0.00
+100.00%
-0.36
—
Sale Of Business
—
0.00
-100.00%
5.00
-68.09%
15.67
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category